Review Article
Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Table 1
Principal clinical trials of chemotherapy plus Rituximab versus chemotherapy alone in NHL.
| Lymphoma Subtype | Treatment | Patients (no.) | % Overall response rate ( value)* | Median Follow-up (mo.) | Reference |
| Follicular | CVP versus R-CVP | 321 | 57 versus 81 (<.001) | 53 | Marcus et al. [28] | Follicular | CHOP versus R-CHOP | 428 | 90 versus 96 (=.011) | 18 | Hiddemann et al. [29] | Follicular | CHOP versus R-CHOP | 465 | 72.3 versus 85.1 (<.001) | 39,4 | van Oers et al. [30] | Follicular | FCM versus R-FCM | 176 | 71 versus 95 (=.01) | 26 | Forstpointner et al. [31] | Follicular | MCP versus R-MCP | 201 | 75 versus 92 (=.009) | 47 | Herold et al. [32] | relapsed/refractary low grade | R | 37 | 46 | 13,4 | Maloney et al. [33] | relapsed/refractary low grade | R | 30 | 47 | 19 | Feuring-Buske et al. [34] | relapsed/refractary low grade | R | 166 | 48 | 19,5 | McLaughlin et al. [35] | DLBCL | CHOP versus R-CHOP | 399 | 63 versus 76 (=.005)* | 24 | Coiffier et al. [36] | DLBCL | CHOP versus R-CHOP | 824 | 84 versus 93 (=.0001)** | 34 | Pfreundschuh et al. [37] | DLBCL | CHOP versus R-CHOP | 632 | 57 versus 67 (=.05)** | 42 | Habermann et al. [38] | DLBCL | CHOP versus R-CHOP | 122 | 75 versus 94 (=.0054) | 18 | Lenz et al. [39] | B-CLL | FC versus R-FC | 552 | 58 versus 69.9 (=.0034) | 25 | Robak et al. [40] | B-CLL | FC versus R-FC | 817 | 82.5 versus 87.2 (=.012)** | 37,7 | CLL8- German CLL Study Group*** [41] |
|
|
*CR, CR-unconfirmed, partial response.
**CR rate.
***3-year OS.
|